Active, not recruitingPhase 2NCT03407144
Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667)
Studying Classic Hodgkin lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Merck Sharp & Dohme LLC
- Principal Investigator
- Medical DirectorMerck Sharp & Dohme LLC
- Intervention
- pembrolizumab(biological)
- Enrollment
- 340 enrolled
- Eligibility
- 3-25 years · All sexes
- Timeline
- 2018 – 2026
Study locations (30)
- Children's Hospital of Alabama ( Site 0023), Birmingham, Alabama, United States
- Phoenix Childrens Hospital ( Site 0034), Phoenix, Arizona, United States
- Arkansas Children's Hospital ( Site 0046), Little Rock, Arkansas, United States
- Kaiser - Orange County ( Site 0084), Anaheim, California, United States
- Kaiser Permanente ( Site 0082), Downey, California, United States
- Kaiser - Fontana ( Site 0083), Fontana, California, United States
- MemorialCare Health System - Long Beach Medical Center-Cherese Mari Laulhere Children's Village ( Si, Long Beach, California, United States
- Kaiser Permanente Downey Medical Center ( Site 0024), Los Angeles, California, United States
- Kaiser Permanente - Oakland ( Site 0047), Oakland, California, United States
- Kaiser Permanente - Roseville ( Site 0080), Roseville, California, United States
- Kaiser Permanente - Santa Clara ( Site 0079), Santa Clara, California, United States
- Children's Hospital - Colorado ( Site 0028), Aurora, Colorado, United States
- Connecticut Children's Medical Center ( Site 0045), Hartford, Connecticut, United States
- Yale Cancer Center ( Site 0061), New Haven, Connecticut, United States
- Children's National Medical Center ( Site 0090), Washington D.C., District of Columbia, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03407144 on ClinicalTrials.govOther trials for Classic Hodgkin lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07275216Pembrolizumab in Combination With Chemotherapy for the Treatment of Frail Hodgkin Lymphoma Patients Ineligible for Standard TreatmentCity of Hope Medical Center
- RECRUITINGPHASE2NCT07209059PET-Adapted First-Line Therapy With Nivolumab for Advanced Hodgkin LymphomaNational Research Center for Hematology, Russia
- RECRUITINGPHASE2NCT06984146Nivo40-AVD for Advanced Classic Hodgkin LymphomaNational Medical Research Radiological Centre of the Ministry of Health of Russia
- RECRUITINGPHASE2NCT06745076Personalized Reduction of Chemotherapy Intensity Through ctDNA Evaluation for the Treatment of Patients With Advanced Hodgkin LymphomaUniversity of Washington
- RECRUITINGPHASE1, PHASE2NCT06642792A Study of AK129 With or Without AK117 in PD(L)1-refractory Classic Hodgkin LymphomaAkeso
- RECRUITINGPHASE2NCT06377540MT2022-60: Ph 2 Study of Pembro+ BEAM With ASCT for Relapsed Hodgkin LymphomaMasonic Cancer Center, University of Minnesota
- RECRUITINGPHASE2NCT07234487Comparison of AVD + Low-Dose Nivolumab vs. PET-Adapted BEACOPP-like in Advanced cHLSt. Petersburg State Pavlov Medical University
- RECRUITINGPHASE2NCT06812858PD-1 Inhibitors Maintenance for cHL Post-autoHCTSt. Petersburg State Pavlov Medical University